Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse

Neurobiology of Aging

Volumn 25, Issue 1, 2004, Pages 131-138

  Ren, Jun ^a,b   Porter, James E ^a   Wold, Loren E ^a   Aberle II, Nicholas S ^a   Muralikrishnan, Dhanasekaran ^a   Haselton, James R ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

Contraction; Intracellular Ca2+ transients; Parkinson disease; Receptor binding; Relaxation; Ventricular myocytes

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; ISOPRENALINE; NORADRENALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CELL ISOLATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROSTIMULATION; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE; MALE; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM; VELOCITY;

EID: 0347481461     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(03)00035-6     Document Type: Article

References (36)

1. Ambrosio S., Mahy N. Acute peripheral catecholaminergic changes in rat after MPTP and MPP+ treatment. Rev. Esp. Fisiol. 45:1989;157-161.
2. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
3. 123I ]iodobenzylguanidine in Parkinson's disease with autonomic failure Acta Neurol. Scand. 97:1998;307-314.
4. 123I ]MIBG separates Parkinson's disease from multiple system atrophy Neurology. 53:1999;1020-1025.
5. Dae M.W., O'Connell J.W., Botvinick E.H., Ahearn T., Yee E., Huberty J.P.et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 79:1989;634-644.
6. Druschky A., Hilz M.J., Platsch G., Radespiel-Troger M., Druschky K., Kuwert T.et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J. Neurol. Sci. 175:2000;3-12.
7. Fuller R.W., Hemrick-Luecke S.K., Robertson D.W. Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4- phenylpyridinium (MPP+) effects on mouse heart norepinephrine. Biochem. Pharmacol. 37:1988;3343-3347.
8. Fuller R.W., Hemrick-Luecke S.K., Perry K.W. Tissue concentrations of MPTP and MPP+ in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice. Life Sci. 45:1989;2077-2083.
9. Gill J.S., Hunter G.J., GANE G., Camm A.J. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled meta-iodobenzylguanidine scintigraphy. Am. Heart J. 126:1993;390-398.
10. Glowniak J.V., Kilty J.E., Amara S.G., Hoffman B.J., Turner F.E. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J. Nucl. Med. 34:1993;1140-1146.
11. Goldstein D.S., Holmes C., Sheng-Ting L., Bruce S., Metman L.V., Cannon R.O. III Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 133:2000;338-347.
12. Goldstein D.S., Holmes C., Cannon R.O. III, Eisenhofer G., Kopin I.J. Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 336:1997;696-702.
13. Hakusui S., Yasuda T., Yanagi T., Tohyama J., Hasegawa Y., Koike Y., Hirayama M., Takahashi A. A radiological analysis of heart sympathetic functions with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J. Auton. Nerv. Syst. 49:1994;81-84.
14. Iwanaga K., Wakabayashi K., Yoshimoto M., Tomita I., Satoh H., Takashima H.et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology. 52:1999;1269-1271.
15. Iwasa K., Nakajima K., Yoshikawa H., Tada A., Taki J., Takamori M. Decreased myocardial 123I-MIBG uptake in Parkinson's disease. Acta Neurol. Scand. 97:1998;303-306.
16. Minardo J.D., Tuli M.M., Mock B.H., Weiner R.E., Pride H.P., Wellman H.N.et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 78:1988;1008-1019.
17. Motulsky H.J., Ransnas L.A. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1:1987;365-374.
18. Orimo S., Ozawa E., Nakade S., Sugimoto T., Mizusawa H. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 67:1999;189-194.
19. a of aspartic acid 125: Evidence for a salt-bridge interaction and role in Alpha-1b adrenergic receptor activation. J. Pharmacol. Exp. Ther. 292:2000;440-448.
20. Ren J., Brown-Borg H.M. Impaired cardiac excitation-contraction coupling in ventricular myocytes from Ames dwarf mice with growth hormone/insulin-like growth factor I deficiency. Growth Horm. IGF Res. 12:2002;99-105.
21. Ren J., Wold L.E., Natavio M., Ren B.H., Hannigan J.H., Brown R.A. Influence of prenatal alcohol exposure on myocardial contractile function in adult rat hearts: role of intracellular calcium and apoptosis. Alcohol Alcohol. 37:2002;30-37.
22. Satoh A., Serita T., Seto M., Tomita I., Satoh H., Iwanaga K.et al. Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J. Nucl. Med. 40:1999;371-375.
23. Sisson J.C., Shapiro B., Meyers L., Mallette S., Mangner T.J., Wieland D.M.et al. Metaiodobenylguanidine to map scintigraphically the adrenergic nervous system in man. J. Nucl. Med. 28:1987;1625-1636.
24. Sisson J.C., Wieland D.M., Sherman P., Mangner T.J., Tobes M.C., Jacques S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J. Nucl. Med. 28:1987;1620-1624.
25. Sisson J.C., Bolgos G., Johnson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am. Heart J. 121(Pt 1):1991;1119-1123.
26. Sisson J.C., Lynch J.J., Johnson J., Jaques S. Jr., Wu D., Bolgos G.et al. Scintigraphic detection of regional disruption of adrenergic neurons in the heart. Am. Heart J. 116(Pt 1):1988;67-76.
27. Sundström E., Strömberg I., Tsutsumi T., Olson L., Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405:1987;26-38.
28. Takatsu H., Nishida H., Matsuo H., Watanabe S., Nagashima K., Wada H.et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med. 41:2000;71-77.
29. Taki J., Nakajima K., Hwang E.H., Matsunari I., Komai K., Yoshita M.et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med. 27:2000;566-573.
30. Tobes M.C., Jaques S., Wieland S., Sisson J.C. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J. Nucl. Med. 26:1985;897-907.
31. Usha R., Muralikrishnan D., Thomas B., Ghosh S., Mandal C., Mohanakumar K.P. Region-specific attenuation of a trypsin-like protease in substantia nigra following dopaminergic neurotoxicity by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Brain Res. 882:2000;191-195.
32. Vatner D.E., Lavallee M., Amano J., Finizola A., Homcy C.J., Vatner S.F. Mechanisms of supersensitivity to sympathomimetic amines in the chronically denervated heart of the conscious dog. Circ. Res. 57:1985;55-64.
33. Wallace R.A., Boldry R., Schmittgen T., Miller D., Uretsky N. Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart. Life Sci. 35:1984;285-291.
34. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J. Neurol. Sci. 155:1998;60-67.
35. Yoshita M., Hayashi M., Hirai S. Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl. Med. Commun. 19:1998;137-142.
36. 2-adrenergic receptor. J. Biol. Chem. 273:1998;3401-3407.